Latest Administration News

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

Inghams Group reported a stable underlying EBITDA of $236.4 million for FY25 despite softer market conditions and customer changes, while guiding for a modest earnings dip in FY26 as cost reduction programs take effect.

Guzman y Gomez (GYG) has reported a record FY25 with $1.2 billion in network sales and a 152% jump in net profit, underpinned by strong comp sales growth and rapid restaurant expansion. The company also declared its first dividend and outlined ambitious plans for continued growth and margin improvement.

Inghams Group Limited reported a 3.4% revenue decline and an 11.5% drop in net profit for FY25, impacted by a new Woolworths supply agreement and lease accounting changes, while maintaining stable underlying earnings and declaring an 8-cent fully franked final dividend.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

BSP Financial Group reported a solid 9.8% increase in net profit for the half year ended June 2025, underpinned by growth in net interest income, fees, and foreign exchange earnings. The Group also restructured its Fiji operations into a wholly owned subsidiary, enhancing its regional footprint and regulatory compliance.

Brazilian Critical Minerals secures robust support from Amazonas state and local authorities for its Ema Rare Earth Project, advancing environmental permitting with unanimous community approval.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

The Federal Court has approved the transfer of Centrex Limited’s shares to PRL Global, marking the end of Centrex’s external administration and a new chapter as a PRL subsidiary.

Charter Hall Long WALE REIT (ASX, CLW) has announced the reactivation of its Distribution Reinvestment Plan (DRP) for the upcoming September 30, 2025 quarterly distribution, offering investors a cost-effective way to reinvest dividends.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.